Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948763 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03948763 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 70 participants.
The verdict
NCT03948763, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL V941
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03948763
The ClinicalTrials.gov registry entry for NCT03948763 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03948763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03948763 about?
NCT03948763 is a clinical study titled "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)". This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
What is the current status of trial NCT03948763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2019-06-26. Estimated completion is 2022-08-25.
What interventions are being tested in trial NCT03948763?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), V941 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03948763?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.